CMV Retinitis Retreatment Trial
Cytomegalovirus Retinitis, HIV Infections
About this trial
This is an interventional treatment trial for Cytomegalovirus Retinitis focused on measuring Retinitis, Ganciclovir, Foscarnet, Cytomegalovirus Infections, Acquired Immunodeficiency Syndrome
Eligibility Criteria
Inclusion Criteria Required: At least 28 days of prior foscarnet or ganciclovir. Concurrent Medication: Allowed: G-CSF. Recommended: Antiretroviral therapy. Patients must have: HIV infection or AIDS. Active CMV retinitis after 28 or more days of either foscarnet or ganciclovir therapy. At least one lesion with one-quarter disk area or more that can be photographed. Visual acuity of 3 or more letters on ETDRS chart (5/200 Snellen) in an affected eye. Exclusion Criteria Co-existing Condition: Patients with the following symptoms and conditions are excluded: Media opacity severe enough to preclude visualization of both fundi. Retinal detachment not scheduled for surgical repair. Patients with the following prior conditions are excluded: History of intolerance to ganciclovir or foscarnet sufficient to contraindicate use. History of combination foscarnet/ganciclovir therapy. Active drug or alcohol abuse sufficient to prevent compliance.
Sites / Locations
- UCSD - Shiley Eye Ctr / SOCA
- UCLA - Jules Stein Eye Institute / SOCA
- UCSF - San Francisco Gen Hosp
- Northwestern Univ / SOCA
- Johns Hopkins Hosp / SOCA
- New York Univ Med Ctr / SOCA
- New York Hosp - Cornell Med Ctr / Sloan - Kettering / SOCA
- Mount Sinai Med Ctr / SOCA
- Univ of North Carolina / SOCA